1447 results about "Methyl Donors" patented technology

A compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof wherein X-Y is -NHSO2- or -SO2NH-; R1 is H, CN or alkyl; R2 is selected from COOH and a tetrazolyl group; R3 is selected from H, Cl and alkyl; R4 is selected from H and halo; R5 is selected from H, alkyl, haloalkyl, SO2-alkyl, Cl, alkoxy, OH, CN, hydroxyalkyl, alkylthio, heteroaryl, cycloalkyl, heterocycloalkyl and haloalkoxy; R6 is H; R7 is selected from H, CN, haloalkyl, halo, SO2-alkyl, optionally substituted heteroaryl, SO2NR14R15, CONR10R11 and alkyl; R8 is selected from H, alkyl, haloalkyl and halo; R9 is H or halo; and R10, R11, R12, R14, and R15 are H or alkyl; R13 is selected from alkyl, halo, alkoxy, CN, haloalkyl and OH; and m is 0-3. The compounds of formula (I) modulate ERAP1 (endoplasmic reticulum aminopeptidase 1) and are for use in treating proliferative, immune or inflammatory disorders, particularly cancer or leukemia. The compounds of formula (I) stimulate a neo-antigen directed immune response in the subject. A method for producing an antigen-presenting cell which presents a neo-antigen using compounds of formula (I) is disclosed. An immunogenic composition comprising an antigen-presenting cell is also disclosed. Exemplified compounds include 4-cyclopropyl-3-(N-(2-(morpholin-3-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid.

Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof. Another method includes: administering once-daily to the subject in need thereof, an oral load dose formulation having from 240 mg to 480 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof, and thereafter administering once-daily to the subject, an oral maintenance dose formulation having 80 mg to 160 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.

The invention provides an UTR element NHP1 as well as a construction method and application thereof, and relates to the technical field of mRNA. A 5 'UTR with a good expression effect is designed by integrating dominant sequences of a human high-expression gene and a pathogen natural UTR, a chimeric structure NHP1 with high ribosome load is predicted through a calculation model, a DNA sequence of the NHP1 is as shown in SEQ NO 1, and an RNA sequence of the NHP1 is as shown in SEQ NO 2; an EGFP report system is adopted on the DNA level to rapidly screen UTR; the translation efficiency is quantitatively evaluated on the RNA level through luciferase mRNA (N1-methyl pseudouridine modification); and the particle size is controlled by a microfluidic technology, so that the optimized UTR-mRNA is efficiently expressed after being delivered.

The invention provides a kit and a detection method for detecting Alzheimer disease related proteins in human blood. The kit comprises a microsphere solution coupled with a p-Tau-217 capture antibody, a microsphere solution coupled with a p-Tau-231 capture antibody, a fluorescein PE coupling detection antibody solution and a diluent, the diluent is prepared from tris (hydroxymethyl) aminomethane, Triton X-100, sodium chloride and Proclin300; according to the kit provided by the invention, the accuracy of detecting the p-Tau-217 protein and the p-Tau-231 protein is improved by designing the microspheres, specifically detecting the p-Tau-217 protein and the p-Tau-231 protein and using a double-antibody sandwich detection method, clinical detection application is more convenient, and the kit is high in specificity, high in sensitivity, good in repeatability and relatively good in application prospect.

The invention relates to the field of sponge materials, and provides an antibacterial degradable sponge material and a preparation method thereof. The material is prepared from protocatechuic acid modified quaternized chitosan, quaternary ammonium salt grafted gelatin, sodium alginate, polyhydroxybutyrate, polycaprolactone, a polylactic acid-glycolic acid copolymer, hexamethylene diisocyanate, a foaming agent, nano cellulose, vitamin E, polyethylene glycol, triethylamine and dimethylformamide. Protocatechuic acid and quaternized chitosan are subjected to amidation modification, and chitosan and gelatin are subjected to quaternization treatment by adopting 2, 3-epoxypropyl trimethyl ammonium chloride, so that the antibacterial property and biodegradability of the material are improved. In the material preparation process, through vacuum degassing, foaming vacuum degree and humidity control and a multi-step drying process, it is ensured that the average pore size of the material is uniform (50-200 microns) and the porosity is high (50%-90%), and the obtained material has excellent antibacterial property and degradability and has wide application value.

The invention relates to a molecular marker related to the content of 2-acetyl-3-methylpyrazine in pig muscle and application of the molecular marker, belonging to the technical field of determination or inspection methods of enzymes, nucleic acids or microorganisms. The technical problem to be solved by the invention is to provide a molecular marker related to the content of 2-acetyl-3-methylpyrazine in pig muscle. In order to solve the technical problem, the molecular marker provided by the invention is obtained through genome-wide association (GWAS) analysis, the nucleotide sequence of the molecular marker is as shown in SEQ ID NO: 1, and the molecular marker has an Agt at the 6328556 position of a chromosome 9 of a pig genome; a nucleotide single base of G is mutated, and the mutation obviously affects the content of 2-acetyl-3-methylpyrazine in pig muscles. By detecting the genotype of a to-be-detected pig at the SNP site, early selection of the content of 2-acetyl-3-methylpyrazine in pig muscles can be realized.

The invention relates to hydrogel loaded with oxygen self-producing nanoparticles as well as a preparation method and application of the hydrogel. The preparation method comprises the following steps: 1, taking cross-linked methacrylamide silk fibroin and hyaluronic acid modified by arginine-glycine-aspartic acid peptide as base materials, and loading self-oxygen-producing nano particles CaO2 (at) PVP (at) Cu-EGCG, and the self-oxygen-producing nano particles CaO2 (at) PVP (at) Cu-EGCG are prepared by coating Cu-EGCG on calcium peroxide nano particles modified by PVP modified polyvinylpyrrolidone. The hydrogel can improve energy metabolism and regulate immune environment through dual mechanisms, realizes efficient promotion of myocardial repair, and provides a new strategy and thought for tissue regeneration and functional recovery after myocardial infarction.

The invention relates to a cartilage organ constructed on the basis of a DNA-silk fibroin hybrid hydrogel sustained-release system as well as a preparation method and application of the cartilage organ. The DNA-silk fibroin hybrid hydrogel sustained-release system is a hydrogel system formed by printing a DNA-silk fibroin hybrid hydrogel sustained-release system premix solution through a digital light processing system, and the DNA-silk fibroin hybrid hydrogel sustained-release system premix solution contains DNA, silk fibroin, acryloylated RGD peptide, acryloylated polyethylene glycol NHS ester, glucosamine, TD-198946 and 2, 4, 6-trimethyl-1, 3-pentanediol. The invention discloses a lithium 2, 6-trimethylbenzoyl phosphate. Compared with the prior art, the glucosamine and the TD-198946 introduced into the DNA-silk fibroin hybrid hydrogel sustained-release system disclosed by the invention can be used for remarkably improving and promoting the cartilage differentiation efficiency of the bone marrow mesenchymal stem cells; the cartilage graft can be transplanted to a cartilage defect position as a cartilage graft to promote cartilage regeneration and repair.

The invention provides a fusion protein with a tribasic group editing function and application thereof, and relates to the technical field of basic group editing. The fusion protein comprises adenine deaminase, N-methylpurine DNA (deoxyribonucleic acid) glycosylase and nuclease. Aiming at the problem that an existing base editing tool cannot edit by taking three bases as substrates at the same time, the invention provides a novel three-function base editor which is named as A, Camp; and G-BE. A, Camp; the G-BE can be edited by independently using A, C and G as substrates to realize the editing activity of A-G / T / C, C-T / G / A and G-T / A / C, and can also be edited by simultaneously using A, C and G as substrates on alleles.

The invention discloses an ovarian protection composition containing ergothioneine and a preparation method of the ovarian protection composition, and relates to the technical field of ovarian protection compositions. The ovary protection composition containing the ergothioneine is prepared from the following components in parts by mass: 0.1 to 0.5 part of the ergothioneine, 0.05 to 1 part of S-equol, 1 to 5 parts of reducing coenzyme Q10, 1 to 3 parts of vitamin E, 10 to 20 parts of chitosan oligosaccharide, 30 to 50 parts of microcrystalline cellulose, 3 to 8 parts of hydroxypropyl methyl cellulose, 0.5 to 2 parts of silicon dioxide and 0.5 to 2 parts of a stabilizer. By adopting the stabilizer, photooxidation and hydrolysis of sensitive components are inhibited through molecular action, and the long-term stability of the composition in a humid and hot environment is remarkably improved in combination with the physical barrier action of silicon dioxide. Through the antioxidant synergistic effect of the ergothioneine and the vitamin E, the hormone regulation effect of the S-equol and the energy metabolism improvement effect of the coenzyme Q10, a multi-layer ovarian function protection system is constructed, and the health state of ovaries is improved. Through a special process, the tablet can be rapidly disintegrated and slowly released in an intestinal targeted manner, burst release of active ingredients is avoided, and the absorption efficiency is improved.

The invention provides a modified porous chitosan gel bead, a preparation method thereof and application of the modified porous chitosan gel bead in cobalt-nickel separation, and belongs to the technical field of chitosan preparation. The preparation method comprises the following steps: firstly, modifying chitosan by using polyethylene glycol and glutaraldehyde to obtain a porous chitosan gel bead with a cross-linked structure, and then grafting by using epichlorohydrin, ethylenediamine and 2-chloromethylpyridine hydrochloride to obtain the modified porous chitosan gel bead containing an aminomethylpyridine functional group. The modified porous chitosan gel bead has excellent selective adsorption on nickel ions in a cobalt-nickel solution with the pH value range of 2-5, and nickel-cobalt separation can be achieved. In addition, the modified porous chitosan gel bead also has a good nickel-cobalt separation effect in a salt-containing system. The preparation method of the modified porous chitosan gel bead provided by the invention is simple in process, and the raw material chitosan is wide in source, non-toxic and environment-friendly.

The present invention relates to compounds (I) possessing an indole moiety linked to an isoindoline moiety, to compounds having similar core structures, and to associated salts, solvates, prodrugs and pharmaceutical compositions. The present invention further relates to methods of synthesising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by Factor B inhibition.

The invention belongs to the field of pharmaceutical analysis, and discloses a method for simultaneously determining the contents of tolperidone hydrochloride, methyl hesperidin and vitamin B6 in Naoluotong capsules, the method comprises three steps of preparation of a mixed reference solution, preparation of a test solution and content determination, and the chromatographic conditions of the content determination are as follows: a C18 chromatographic column, a C18 chromatographic column, a C18 chromatographic column, a C18 chromatographic column, a C18 chromatographic column, a C18 chromatographic column, a C18 chromatographic column, a C18 chromatographic column and a C18 chromatographic column; a mobile phase is methanol (A)-0.1% glacial acetic acid solution (B), gradient elution is carried out for 0-5 min, and 96% of B is obtained; 5-6 min, 96%-60% of B is selected; 6-20 min, the content of B is 60%-50%; the volume flow rate is 1.0 ml / min; the column temperature is 30 DEG C; the detection wavelength is 291 nm; the sample size is 1 microliter. According to the method, synchronous detection of three components (tolperidone hydrochloride, methyl hesperidin and vitamin B6) with remarkable physicochemical property difference can be realized, the chromatographic condition is simple, and the detection speed is high.

The invention discloses a preparation method of a sandwich structure immunosensor based on surface enhanced Raman scattering and application of the sandwich structure immunosensor to detection of an anti-phospholipase A2 receptor antibody, and is characterized by comprising the following steps: sputtering silver ions on a cotton swab / ZIF-67 prepared by an in-situ growth method by adopting an ion sputtering method to obtain a cotton swab / ZIF-67 / Ag NPs composite material; the preparation method comprises the following steps: preparing an antigen solution, then adding the antigen solution into the antigen solution to obtain an immune substrate, adding a methylene blue aqueous solution into a silver nanoparticle solution for reaction, then connecting an anti-human PLA2R IgG antibody to obtain an immune probe, and finally dropwise adding a phosphate buffer solution containing an antibody to be detected onto the immune substrate, and dropwise adding the immune probe solution to the immune substrate adsorbed with the antibody to be detected to obtain the sandwich structure immunosensor based on surface enhanced Raman scattering. The method has the advantages of high sensitivity, good selectivity and strong stability.

The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.

The invention relates to a TSV (through silicon via)-based copper / titanium / TEOS (tetraethyl orthosilicate) rate selective control CMP (chemical mechanical polishing) solution. The polishing solution is prepared from nanoscale silicon dioxide, a complexing agent, an inhibitor, a surfactant, an oxidizing agent and deionized water, the pH value of the alkaline polishing solution is 8.0; the invention discloses a polishing solution. 2, 2 '-[[((methyl-1H-benzotriazole-1-yl) methyl] imino] diethanol (TT-LYK) and octyl hydroxamic acid (OHA) are used as inhibitors, the two inhibitors act independently or are compounded, and under the synergistic effect of the inhibitors and the complexing agent, the polishing solution has the high polishing rate and the good surface quality performance, meanwhile, the rate of copper / titanium / TEOS can be selectively controlled, and the polishing effect is good. And dish-shaped recesses and dielectric layer erosion after polishing are improved. The polishing solution prepared by the invention is simple in preparation process and easy for large-scale production, and meets the actual requirements of industrial application.

The invention belongs to the technical field of dressing preparation, and particularly relates to a preparation method of a photocuring methacrylated gelatin hydrogel dressing, which comprises the following steps: step 1, dissolving methacrylated gelatin in a phosphate buffer solution to prepare a methacrylated gelatin solution with the mass concentration of 5-15%; 2, adding a natural photoinitiator into the solution obtained in the step 1, and uniformly stirring and mixing; 3, adding the traditional Chinese medicine active ingredient powder, and stirring until the powder is uniformly dispersed to obtain a mixed solution; and 4, pouring the mixed solution into a mold, and curing and molding under the irradiation of visible light. Chlorophyll or riboflavin is used as a natural photoinitiator and is directly dispersed in a methacrylated gelatin solution in a physical blending mode, a curing light source enables chlorophyll to completely avoid a chemical initiator, meanwhile, the process is simplified into physical stirring to replace nanoparticle synthesis and modification, visible light reduces the risk of tissue burn, the production cost is reduced, and the method is suitable for industrial production. The method is suitable for primary medicine.

The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.

The present invention relates to solid forms of the poly(ADP-ribose) polymerase 7 (PARP7) inhibitor 5-[[(2S)-1-(3-oxo-3-[4-[5-(trifluoromethyl)pyrimidin-2-yl]piperazin-1-yl]propoxy)propan-2-yl]amino]-4-(trifluoromethyl)-2,3-dihydropyridazin-3-one, and salts thereof, including methods of preparation thereof, where the inhibitor is useful in the treatment of cancer.

The invention relates to the technical field of biomedical dressings, in particular to a dressing for a diabetic foot wound surface and a preparation method of the dressing. 0.2 to 0.8 part of reduced graphene oxide; 2 to 5 parts of beta-1, 3-glucan modified by chondroitin sulfate; 0.08 to 0.3 part of silver nitrate; 3 to 7 parts of N-isopropyl acrylamide-co-acrylic acid; 0.15 to 0.4 part of N, N '-methylene bisacrylamide; 2 to 5 parts of sulfhydrylated hyaluronic acid; 0.3 to 0.8 part of D-alpha-vitamin E polyethylene glycol succinate; 2 to 5 parts of amino-functionalized mesoporous silica; 1 to 3 parts of L-arginine-L-glutamate; 0.1 to 0.4 part of genipin; the super-strong mechanical property and the super-strong flexibility are realized, so that the dressing can better adapt to the irregular shape of a wound surface, and continuous protection is provided.

The present disclosure relates to pharmaceutically acceptable salts, cocrystals, and crystalline forms thereof, of a compound which is N—((S)-1-(3-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl)-6-(3-methyl-3-(methylsulfonyl)but-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2- ((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-TH-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide, which is useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.

Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof. Another method includes: administering once-daily to the subject in need thereof, an oral load dose formulation having from 240 mg to 480 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof, and thereafter administering once-daily to the subject, an oral maintenance dose formulation having 80 mg to 160 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.

The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.

The invention relates to the technical field of diagnosis markers and diagnosis methods for mental diseases of children and adolescents, in particular to a plasma metabolism diagnosis marker and diagnosis system for depression of children and adolescents. The plasma metabolism diagnosis marker comprises at least one of cyclic adenosine monophosphate, methylpyridine, unsaturated undecylenyl carnitine, histidine, prolyl hydroxyproline, tryptophan and glucuronic acid. According to the scheme, non-target metabonomics data is analyzed, and seven candidate diagnostic markers for depression of children and adolescents are screened and determined from common differential metabolites. Then, through targeted metabonomics research, diagnostic markers and combinations thereof with ideal diagnostic effects are determined, and then a diagnostic model is constructed. And a sex factor is also incorporated into the diagnosis model, so that the diagnosis effect is further improved. According to the technical scheme, the technical problem that in the prior art, reliability and popularization potential of depression plasma metabolism biomarkers of children and adolescents are not ideal can be solved, and the depression plasma metabolism biomarkers have ideal popularization and application prospects.

Aspects of the present disclosure are directed to methods, compositions, and kits for detection and analysis of DNA and RNA cytosine methylation. Certain aspects include methods, compositions and kits useful in bisulfite sequencing of methylated nucleic acids, including methylated nucleic acids from low-input samples such as cell-free DNA and cell-free RNA. Also disclosed are methods and compositions for detection and quantification of 5-hydroxymethylcytosine in DNA.

The invention provides a bio-based chain extender and application thereof, the bio-based chain extender comprises a bio-based compound 2, 5-bark dimethyl casein and / or 5-shin methyl-2-bark methyl casein, and the bio-based compound 2, 5-bark dimethyl casein and / or 5-shin methyl-2-bark methyl casein is used as the bio-based chain extender to synthesize modified polyurethane with antibacterial and mildew-proof performance. The polyurethane glycoside material can be endowed with lasting, stable and broad-spectrum antibacterial performance and mildew-proof performance, an antibacterial agent does not need to be additionally added, and the problems of environmental pollution, short antibacterial time, unstable antibacterial performance and the like caused by migrating of the antibacterial agent in the use process of the polyurethane glycoside material are solved; particularly, the bio-based chain extender is a bio-based source, is safe and environment-friendly, has a remarkable antibacterial and anti-withering modification effect on a polyurethane material, and has a wide application prospect in the fields of medical materials, public facilities, health protection and the like.

The invention relates to a preparation method of a sodium alginate composite hydrogel microneedle for treating pathological scars, and belongs to the technical field of hydrogel microneedles, the microneedle takes sodium alginate as a main material, the sodium alginate is methylated to obtain methylacryloylated sodium alginate AlgMA, hollow manganese dioxide nanoparticles loaded with matrix metalloproteinase are added, and the microneedle is prepared by a hydrothermal method. A hydrogel microneedle filling solution is obtained; the preparation method comprises the following steps: transferring the hydrogel microneedle into a PDMS microneedle mold, carrying out negative pressure vacuum bubble removal, drying and concentrating twice in a drying oven, carrying out photopolymerization crosslinking, forming a solid hydrogel microneedle tip, adding a 20% PVA solution, and drying in the drying oven to form the microneedle substrate, and the preparation method is simple, convenient and efficient, has industrial application potential, and is suitable for the scenes of drug delivery, skin care and the like; according to the application of the sodium alginate composite hydrogel microneedle in pathological scar drug delivery, the sodium alginate composite hydrogel microneedle has excellent mechanical strength and biocompatibility, and painless and noninvasive drug delivery can be carried out on the surface of scar skin.

The invention belongs to the technical field of polyether refining, and particularly relates to a methyl-terminated polyether refining treatment method. Comprising the following steps: adding water into a to-be-refined methyl-terminated polyether sample, stirring, dissolving salt in water, layering, adding water into a polyether layer again after separation, stirring, layering, and separating to obtain a primary sample; taking a methyl-terminated polyether sample to be refined again, heating, adding water, adjusting the pH with acid, and stirring to obtain a sample A; adding the preliminary sample into the sample A, and stirring to obtain a sample B; and adding acid into the sample B to adjust the pH value, continuously stirring, crystallizing the metal salt into large particles, settling, separating out solids, deacidifying and decolorizing, dehydrating in vacuum, and filtering to obtain qualified methyl-terminated polyether products, and intercepting part of qualified products as preliminary samples for continuous production. By adding the methyl-terminated polyether primary finished product, the crystallization process of the metal salt can be effectively improved, so that the metal salt tends to generate coarse particles easy to filter, the filtering resistance is reduced, and the filtering period is shortened.

The invention relates to a high-water-solubility denitroflavin covalent complex as well as a preparation method and application thereof, and belongs to the technical field of organic synthesis and medicinal chemistry. Comprising the following steps: (1) firstly, carrying out bromination reaction on 3-methyl-10-ethyl denitroflavin, so as to obtain 3-methyl-10-(1-bromoethyl) denitroflavin; and (2) coupling the 3-methyl-10-(1-bromoethyl) denitroflavin with vitamin C, so as to obtain the high-water-solubility denitroflavin covalent complex. According to the present invention, the prepared highly water-soluble denitrificin covalent complex has the two-phase solubility of the organic solvent and the water, such that the water solubility of the 3-methyl-10-ethyl-denitrificin is substantially enhanced, and the application range of the denitrificin is expanded. And meanwhile, the denitrified flavin covalent compound also has good antioxidant activity, and the antioxidant duration can be prolonged.